Bortezomib-Mediated Up-Regulation of TRAIL-R1 and TRAIL-R2 Is Not Necessary for but Contributes to Sensitization of Primary Human Glioma Cells to TRAIL

In Response: In their Letter, Kyritsis et al. discussed the interesting question of the contribution of up-regulation of the apoptosis-inducing tumor necrosis factor–related apoptosis inducing ligand (TRAIL) receptors, TRAIL-R1 (DR4) and TRAIL-R2 (DR5), to the sensitization of tumor cells to TRAIL

[1]  J. Meixensberger,et al.  Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis , 2007, Clinical Cancer Research.

[2]  A. Kolb,et al.  TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer‐specific apoptosis within a therapeutic window , 2007, Hepatology.

[3]  G. Cohen,et al.  Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosis , 2006, Cell Death and Differentiation.

[4]  M. Li‐Weber,et al.  Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL , 2005, Hepatology.

[5]  A. Kraft,et al.  The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim , 2005, Molecular Cancer Therapeutics.

[6]  K. Black,et al.  Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM) , 2005, Oncogene.

[7]  Hongmei Yang,et al.  Persistent c-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand–Mediated Apoptosis in Prostate Cancer , 2004, Cancer Research.

[8]  W. Stremmel,et al.  Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs , 2004, Cell Death and Differentiation.

[9]  Henning Walczak,et al.  The interplay between the Bcl-2 family and death receptor-mediated apoptosis. , 2004, Biochimica et biophysica acta.

[10]  P. Elliott,et al.  The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. , 2003, Blood.

[11]  J. Mier,et al.  Phosphatidylinositol 3-Kinase/Akt Activity Regulates c-FLIP Expression in Tumor Cells* , 2001, The Journal of Biological Chemistry.

[12]  H. Kalthoff,et al.  Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis , 2000, Oncogene.

[13]  J. Bruner,et al.  TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation , 2005, Apoptosis.